
OptumRx has recently announced that it is easing its prior authorization (PA) requirements on about 80 drugs for renewed prescriptions. The program is planned to start on May 1, 2025 and will include various drugs such as Aimovig, Kalydeco, and Praluent. The list of drugs is anticipated to increase based on the success of the pilot implementation this year. OptumRx estimates that the program would eliminate about 10% of all pharmacy prior authorizations.
The change is likely to streamline dispensing of the initial 80 drugs, making it easier and less costly for the pharmacies to fill them.